Spastic Cerebral Palsy Clinical Trial
— INCIPITOfficial title:
Prospective, Open-label, Non-randomized, Single-arm, Dose Titration Study to Investigate the Efficacy and Safety of IncobotulinumtoxinA in Children Deemed to Require a Total Body Dose up to 22U/kg (Maximum Dose 550U) During the Study Period for the Treatment of Upper and Lower Limb Spasticity Due to Cerebral Palsy
NCT number | NCT05340439 |
Other study ID # | INCIPIT |
Secondary ID | |
Status | Not yet recruiting |
Phase | Phase 2 |
First received | |
Last updated | |
Start date | June 2022 |
Est. completion date | May 2025 |
Prospective, open-label, non-randomized, single-arm, dose titration, phase II study. The study will consist of three injection cycles. In each, an injection visit is followed by an observation period of 12 to 20 weeks. During cycle 1, a total body dose of 16U/kg (maximum 400U) of IncobotulinumtoxinA will be injected into the spastic muscles of the affected limbs. During cycle 2, a total body dose of 19U/kg (maximum 475U) of IncobotulinumtoxinA will be injected into the spastic muscles of the affected limbs. If a dose of 19U/kg is not justified (i.e., for clinical or safety reasons) but BoNT-A treatment is still needed (according to the clinical condition of patients) the same dose injected in cycle 1 (16U/Kg; maximum 400U) may be administered in the cycle 2. During cycle 3, a total body dose of 22U/kg (maximum 550U) of IncobotulinumtoxinA will be injected into the spastic muscles of the affected limbs. If a dose of 22U/kg is not justified (i.e., for clinical or safety reasons) but BoNT-A treatment is still needed (according to the clinical condition of patients) the same dose injected in cycle 2 (19U/Kg; maximum 475U) may be administered in the cycle 3.
Status | Not yet recruiting |
Enrollment | 30 |
Est. completion date | May 2025 |
Est. primary completion date | January 2024 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 2 Years to 17 Years |
Eligibility | Inclusion Criteria: - Patients with upper and lower limb spasticity due to cerebral palsy - Gross Motor Function Classification System (GMFCS) from Level II to Level V - Selected target clinical pattern diagnosed by a qualified health care professional (i.e. physiatrist) - Focal spasticity scored at least 2 points on the Ashworth scale (AS) in the joints associated with the selected target clinical pattern - Patient deemed by the investigator to require a total body dose up to 22U/kg (maximum 550U) during the study period - In the case of children pretreated with BoNT-A, time from the last injection at least 5 months - Informed consent signed by parents or legal guardian. Exclusion Criteria: - Participation in other trials - BoNT-A treatment contraindicated - Therapy with anticoagulants or other substances that could have an anticoagulant effect - Girls of childbearing potential (defined as females post menarche) - Presence of fixed contractures, or bony deformities of the affected limbs - Previous treatment of spastic muscles with nerve penalization - Other neurological or orthopaedic conditions involving the affected limbs. Specific vulnerable populations: - institutionalized patients will not be included - girls of childbearing potential (defined as females with a history of menarche) will not be included. Withdrawal criteria for single patients: - Serious adverse event (SAE) - Development of dysphagia and/or aspiration pneumonia. - Withdrawal of consent - Inability to follow the study according to its design and time points - Co-administration of aminoglycoside antibiotics, spectinomycin, 4-aminoquinoline, anticholinergic drugs, AbobotulinumtoxinA, OnabotulinumtoxinA or other agents interfering with neuromuscular transmission (e.g., tubocurarine-type muscle relaxants). |
Country | Name | City | State |
---|---|---|---|
n/a |
Lead Sponsor | Collaborator |
---|---|
Universita di Verona |
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Ashworth Scale | The Ashworth scale is a well-known and commonly used scale in clinical trials with spasticity. It will be used to categorize the severity of spasticity by judging resistance to passive movement. It is a 5-point scale that ranges from 0 (=no increase in tone) to 4 (=limb rigid in flexion or extension). | During the screening assessment | |
Primary | Ashworth Scale | The Ashworth scale is a well-known and commonly used scale in clinical trials with spasticity. It will be used to categorize the severity of spasticity by judging resistance to passive movement. It is a 5-point scale that ranges from 0 (=no increase in tone) to 4 (=limb rigid in flexion or extension). | Immediately before each IncobotulinumtoxinA treatment session | |
Primary | Ashworth Scale | The Ashworth scale is a well-known and commonly used scale in clinical trials with spasticity. It will be used to categorize the severity of spasticity by judging resistance to passive movement. It is a 5-point scale that ranges from 0 (=no increase in tone) to 4 (=limb rigid in flexion or extension). | During the follow-up clinical assessment at 4 weeks from each injection | |
Primary | Ashworth Scale | The Ashworth scale is a well-known and commonly used scale in clinical trials with spasticity. It will be used to categorize the severity of spasticity by judging resistance to passive movement. It is a 5-point scale that ranges from 0 (=no increase in tone) to 4 (=limb rigid in flexion or extension). | During the follow-up clinical assessment at 12 weeks from each injection | |
Secondary | REsistance to PAssive movement Scale (REPAS) | The REPAS is a summary 26-item test used to assess resistance to passive movement in all four limbs of the body. It provides a global evaluation of spasticity status, as well as per hemibody and per limb. 16 items describe the condition of both upper limbs, 10 that of both lower limbs. Each item is rated by using the AS. The sum of the values represent the REPAS score which may range from zero (no resistance for any item) to 104 (limbs rigid for all items). | Immediately before each IncobotulinumtoxinA treatment session; at the follow-up clinical assessment at 4 and 12 weeks from each injection | |
Secondary | Gross Motor Function Classification System (GMFCS) | Is a 5 level classification system that describes the gross motor function of people with cerebral palsy (I=can walk indoors and outdoors and climb stairs without using hands for support; II=can climb stairs with a railing, has difficulty with uneven surfaces, inclines or in crowds; III=walks with assistive mobility devices indoors and outdoors on level surfaces, may be able to climb stairs using a railing, may propel a manual wheelchair and need assistance for long distances or uneven surfaces; IV=walking ability severely limited even with assistive devices, uses wheelchairs most of the time and may propel own power wheelchair, standing transfers, with or without assistance; V=has physical impairments that restrict voluntary control of movement, ability to maintain head and neck position against gravity restricted, impaired in all areas of motor function, cannot sit or stand independently, even with adaptive equipment). | During the screening assessment; immediately before each IncobotulinumtoxinA treatment session; at the follow-up clinical assessment at 4 and 12 weeks from each injection | |
Secondary | Visual Analog Scale (VAS) | The VAS, which is a validated, subjective measure for acute and chronic pain. Scores are recorded by making a handwritten mark on a 10-cm line that represents a continuum between "no pain" and "worst pain." | Immediately before each IncobotulinumtoxinA treatment session; at the follow-up clinical assessment at 4 and 12 weeks from each injection | |
Secondary | Goal Attainment scale (GAS) | The GAS measures the extent to which a subject's individual goals are achieved in course of intervention. The subject and treating team have to identify 2 personal goals for each treated limb at each injection cycle. Investigator rates the GAS score for each injection cycle. The degree of goal attainment is rated on a 5-point scale (-2, -1, 0, +1, +2; study baseline set to -1) and in order to account for interindividual differences in the number of goals (positive values indicate higher goal attainment). | Immediately before each IncobotulinumtoxinA treatment session; at the follow-up clinical assessment at 4 and 12 weeks from each injection | |
Secondary | Global Assessment of Efficacy | The Global Assessment of Efficacy, which will be assessed by the investigator, the patient (if possible), and the caregiver using a 4-point Likert scale with the ratings 1 = very good, 2 =good, 3 = moderate, and 4 = poor. | At the follow-up clinical assessment at 4 and 12 weeks from each injection | |
Secondary | Global Assessment of Tolerability | The Global Assessment of Tolerability, which will be assessed by the investigator at each injection cycle control [V3, V6, V9] and end of cycle visits [V4, V7, V10] using a 4-point Likert scale with the ratings 1 = very good, 2 = good, 3 = moderate, and 4 = poor. | At the follow-up clinical assessment at 4 and 12 weeks from each injection |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT05571033 -
Operant Conditioning of the Soleus Stretch Reflex in Adults With Cerebral Palsy
|
N/A | |
Completed |
NCT00011024 -
Prospective Studies of the Use of Self Hypnosis, Acupuncture and Osteopathic Manipulation on Muscle Tension in Children With Spastic Cerebral Palsy
|
Phase 2 | |
Recruiting |
NCT05810779 -
Dynamic Surface Exercise and Trunk Targeted Training in Children With Spastic Cerebral Palsy
|
N/A | |
Completed |
NCT01049581 -
Effects of Pediatric Aquatic Therapy in Children With Spastic Cerebral Palsy
|
N/A | |
Completed |
NCT04634136 -
Full-spectrum Medical Cannabis for Treatment of Spasticity in Patients With Severe Forms of Cerebral Palsy
|
N/A | |
Recruiting |
NCT06070233 -
Radiosurgery Treatment for Spasticity Associated With Stroke, SCI & Cerebral Palsy
|
N/A | |
Completed |
NCT01815814 -
Therapeutic Potential of Myofascial Structural Integration in Children With Cerebral Palsy
|
N/A | |
Recruiting |
NCT05113433 -
Effects of Different Time Period of Standing Frame on Spasticity and Gait in Children With Spastic Cerebral Palsy.
|
N/A | |
Recruiting |
NCT03676439 -
Lateral Cord Magnetic Stimulation For Refractory Spastic Cerebral Palsy
|
Phase 2/Phase 3 | |
Completed |
NCT03708757 -
Effect of Post Isometric Relaxation Technique & Eccentric Muscle Contraction on Hamstring Spasticity in CP
|
N/A | |
Not yet recruiting |
NCT03529682 -
Circuit Training in Children With Cerebral Palsy
|
N/A | |
Not yet recruiting |
NCT06407856 -
Dual Task Training in Spastic Cerebral Palsy
|
N/A | |
Not yet recruiting |
NCT06407921 -
Whole Body Vibration and BOSU Ball in Spastic Cerebral Palsy
|
N/A | |
Not yet recruiting |
NCT06407869 -
Effects of Functional Progressive Strength Training in Children With Spastic Cerebral Palsy
|
N/A | |
Completed |
NCT04078321 -
Evaluation of Multifocal Transcutaneous Electrical Stimulation for Self-treatment Among Children With Cerebral Palsy
|
N/A | |
Active, not recruiting |
NCT06330311 -
Effectiveness of Whole-Body Vibration
|
N/A | |
Terminated |
NCT00955877 -
Extended-release Epidural Morphine for Acute Post-operative Analgesia Following Selective Dorsal Rhizotomy in Children
|
N/A | |
Completed |
NCT02359799 -
Robotic Rehabilitation of Cerebral Palsy
|
N/A | |
Completed |
NCT01147653 -
A Randomized Study of Autologous Umbilical Cord Blood Reinfusion in Children With Cerebral Palsy
|
Phase 2 | |
Recruiting |
NCT04925102 -
Prediction of Recovery in Spastic Cerebral Palsy.
|